Tepnel Appointed Preferred Supplier to AstraZeneca for DNA Extraction Services
News May 04, 2006
Under the terms of this agreement Tepnel has been appointed as a preferred supplier to AstraZeneca for DNA extraction services.
By continuing to provide a high quality service in the market Tepnel will have the opportunity to compete for further business and AstraZeneca will benefit from volume-related discounts.
Ben Matzilevich, CEO, commented, "Following our recent positive preliminary financial results for 2005 we are delighted at being able to announce more good news."
"AstraZeneca is already a valued client that has been working with us for a number of years and this agreement is proof of the high level of client service and technical expertise that we are able to deliver."
"This agreement further strengthens Tepnel’s position in the pharmaceutical industry as one of Europe’s largest providers of DNA extraction services."
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.